All Reports Events Blogs Videos
Showing 187 results
  • Tech Launch Perspective
    July 22, 2026

    Life sciences enterprises are moving beyond isolated generative AI pilots toward governed, multi-agent workflows that support clinical, commercial, and real-world activities. This shift is increasing demand for platforms that combine regulatory-grade data governance, enterprise interoperability, scalable…
  • State of the Market
    June 22, 2026

    Life sciences enterprises are rethinking Customer Relationship Management (CRM) services as commercial transformation becomes more complex, platform-driven, and outcome-focused. As organizations migrate to cloud-based CRM environments, expand their Veeva and Salesforce ecosystems, and navigate increasingly complex…
  • State of the Market
    June 17, 2026

    Banking enterprises are navigating a market shaped by persistent cost pressures, rising exception volumes, evolving regulatory requirements, and growing expectations for faster, more transparent customer journeys. As operations become more technology-driven, buyers are moving beyond labor-led…
  • In the News
    May 14, 2026

    "Shared data allows the life sciences company to view the customer consistently across the organization, which means everyone is trying to drive the same outcomes for the customer instead of having a different view of the…
  • Blog
    May 13, 2026

    Since the launch of Claude Cowork, narratives suggesting that Artificial Intelligence (AI) will replace Software-as-a-Service (SaaS) platforms have gained significant momentum. We previously referred to this trend as the SaaSocalypse.  With the rise in vibe-coding and the rapidly advancing developer tools, many assume enterprises will increasingly build their own…
  • Blog
    April 09, 2026

    Veeva’s acquisition of Ostro reflects a shift in how life sciences engagement is evolving toward a model that is connected, conversational, and increasingly pull-based.  This shift matters because the industry’s commercial engagement model continues to face challenges. Life sciences…
  • Thematic Report
    March 26, 2026

    Pharmaceutical enterprises are reassessing their IT services sourcing strategies amid moderate growth, budget discipline, and rising innovation expectations. As provider consolidation intensifies, a small group of leading providers continues to capture a disproportionate share of enterprise…
  • Blog
    March 24, 2026

    Pharma Customer Relationship Management (CRM) is no longer a winner-takes-all market. For years, pharma CRM decisions were relatively straightforward, not because enterprises lacked strategic intent, but because the market offered limited real choice. That is now changing.  Since the onset of the COVID-19…
  • Tech Provider Spotlight
    March 19, 2026

    Life sciences commercial engagement is undergoing a fundamental transformation as enterprises move from siloed, channel-centric models to coordinated, customer-centric omnichannel strategies. Increasing Healthcare Professionals (HCP) access constraints, evolving customer expectations, proliferation of digital channels, and mounting…
  • Tech Launch Perspective
    Feb. 26, 2026

    Life sciences enterprises are under pressure to accelerate research, improve evidence generation, and operationalize AI across clinical and commercial functions. Fragmented data estates, evolving regulatory requirements, and the growing importance of real-world and genomic data are…
  • Provider Compendium
    Feb. 24, 2026

    The banking and payments operations landscape is transforming as financial institutions seek to modernize legacy environments, enhance operational resilience, and address heightened regulatory and compliance requirements. This compendium presents fact-based profiles of 27 providers supporting banking…
  • State of the Market
    Jan. 15, 2026

    Amid rising regulatory expectations and growing fraud complexity, financial institutions are reengineering Financial Crime and Compliance (FCC) operations to meet demands for agility, cost efficiency, and risk mitigation. This report provides a detailed view of the…
  • Viewpoint
    Jan. 09, 2026

    As pharma enterprises modernize data architectures, automate workflows, and scale AI across the value chain, scientific expertise is becoming essential to realize meaningful outcomes from digital initiatives. Without scientific grounding, digital systems risk producing insights that…
  • See Us At
    Dec. 09, 2025

    Join us for an exclusive evening AR/analyst networking party to kick off the holiday season. It’s a great opportunity to connect, celebrate, and recognize excellence across the analyst and AR community.  Register now This special event will also include the…
  • Press Release
    Dec. 03, 2025

    Everest Group has announced the release of a new Viewpoint report, The Future of CRM in Pharma: A Decision Framework to Navigate the Post Veeva–Salesforce Era, designed to guide pharmaceutical companies through pivotal CRM platform decisions following the conclusion…
  • PEAK Matrix®
    Nov. 27, 2025

    The global banking operations market is significantly transforming, driven by continued regulatory complexities, rising customer expectations, and advances in AI and automation. Financial institutions are rethinking their sourcing models to prioritize domain-rich, technology-enabled partners that can…
  • Viewpoint
    Nov. 10, 2025

    The global Business Process Outsourcing (BPO) industry is undergoing a seismic transformation due to the emergence of autonomous, LLM-powered AI agents that are rapidly changing how services are delivered. This report examines how BPO firms must…
  • Market Insights™
    Nov. 05, 2025

  • Blog
    Nov. 04, 2025

    Banking And Financial Services (BFS) enterprises are accelerating the adoption of agentic Artificial Intelligence (AI) Agents in Banking, autonomous systems that execute multi-step processes, analyze data, and make decisions at scale. From underwriting to fraud detection, these agents are…
  • Viewpoint
    Sep. 30, 2025

    Investment banking enterprises face mounting pressure from volatile macroeconomic conditions, fee compression, disintermediation through special purpose acquisition companies and direct listings, and increasingly complex regulatory mandates such as Basel III/IV, MiFID II, and Dodd-Frank. Traditional human-led…

Items per page